Gregory Piazza & Darsiya Krishnathasan: A Review on Superficial Vein Thrombosis
Gregory Piazza, Director of the Vascular Medicine Section at Brigham and Women’s Hospital, shared on LinkedIn:
”Superficial vein thrombosis is a challenging venous thromboembolic disorder because of the paucity of randomized controlled trial data and limited guidance in the literature.
Despite this, the patient burden is high.
Accordingly, clinicians are often left to “fend for themselves”.
Very proud of this review in JAMA from my research team that gives clinicians and patients some pathways forward.
Our research fellow and a first year medical student at Tufts, Darsiya Krishnathasan, started this as her undergraduate thesis!
An incredible effort with amazing guidance from my colleague, Dr. Behnood Bikdeli”
Read the full article in JAMA.
Article: Superficial Vein Thrombosis. A Review
Authors: Gregory Piazza, Darsiya Krishnathasan, Nada Hamade, Francisco Ujueta, Giovanni Scimeca, Marcos D. Ortiz-Rios, Bridget McGonagle, Jean-Philippe Galanaud, David Jiménez, Manuel Monreal, John Fanikos, Anahita Dua, Leben Tefera, Raghu Kolluri, Sahil A. Parikh, Walter Ageno, Samuel Z. Goldhaber, Jeffrey I. Weitz, Lisa K. Moores, Isabelle Quéré, Behnood Bikdeli
Stay updated on all scientific advances in the field of thrombosis with Hemostasis Today.
-
Dec 19, 2025, 05:54Abdul Mannan: APTT Mixing Studies Confuse a Lot of People
-
Dec 18, 2025, 23:14The “Normal” FVIII Level Trap in Females with Haemophilia
-
Dec 18, 2025, 23:11WFH Expands Multidisciplinary Bleeding Disorder Training in Vietnam
-
Dec 18, 2025, 17:13Daria Camilli on EuroBloodNet and EHC Collaboration for Bleeding Disorders
-
Dec 18, 2025, 16:50Marie Cambot on Innovhem’s Quantification of The HbF/HbS Ratio for SCD
-
Dec 18, 2025, 16:26Yogesh Rathod on Hematological Issues and ICU
-
Dec 18, 2025, 16:09Carlos Doti: I’m Reminded Why ASH is Such a Powerful Close to The Year
-
Dec 18, 2025, 15:23Michael Hadley: Well-Timed ACC Statement Just Out in JACC Journals
-
Dec 18, 2025, 15:12Wolfgang Miesbach on Insights from Guy Young’s ASH2025 Session on Next-Generation Gene Therapy